MOODY’S-ESG-SOLUTIONS
Moody’s today launched Moody’s ESG360™, an easy-to-use platform that provides portfolio managers with ESG analyst-verified scores and modelled ESG and climate intelligence on private and public companies to bring clarity and confidence to investment decisions on environmental, social and governance (ESG) issues.
“To understand the short- and long-term impact of ESG and climate exposures, market participants need a holistic and reliable view of risks and opportunities,” said Andrea Blackman, Managing Director – Global Head of Moody’s ESG Solutions. “The launch of Moody’s ESG360™ demonstrates our commitment to providing comprehensive coverage to help portfolio managers make sustainable decisions with confidence. Coverage is much more than just a number; it’s a commitment to providing granular and clearly defined data, scores, and assessments – all delivered through platforms that meet customer needs.”
Moody’s ESG360™ allows portfolio managers to identify ESG leaders and laggards across themes, sectors, and regions, monitor and report on portfolio level performance across a broad range of research lines, and analyze key risk metrics at both the portfolio and entity level. All data points will be clearly labeled with their relevance to industry standards and traceable to their source.
At launch, Moody’s ESG360™ provides access to Moody’s physical and transition climate risk data sets across a recently expanded universe of 10,000 companies globally. In the coming months, the platform will be further enhanced with Moody’s ESG insights, including coverage of 300 million public and private companies through a combination of modelled and ESG analyst-verified scores.
Driven by a double materiality approach that accounts for both financial and stakeholder impacts, Moody’s ESG data, scores, and assessments provide a comprehensive view of the ESG performance of companies – including small and medium-sized enterprises (SMEs). This enables a unique assessment of how companies can create sustainable value for the environment, society, and stakeholders, as well as how companies are positioned to manage their exposure and response to ESG risks and opportunities.
Alongside Moody’s ESG360™, Moody’s recently launched a corporate engagement platform, Moody’s ESG360™ Connect, which enables corporates to easily connect with Moody’s regarding their sustainability disclosures and ensure accurate representation of their ESG data, ultimately expanding the data coverage that feeds into Moody’s ESG solutions.
To learn more about Moody’s ESG360™ or get a demo, visit: http://www.moodys.com/moodys-esg360 .
Sustainability is at the core of Moody's business, building better business, better lives and better solutions to create long-term value for society, the environment and the economy. For more information on Moody’s sustainability commitments, visit: https://about.moodys.io/sustainability
ABOUT MOODY’S ESG SOLUTIONS
Moody’s ESG Solutions is a business unit of Moody’s Corporation serving the growing global demand for ESG and climate insights. The group leverages data and expertise across ESG, climate risk, and sustainable finance, and aligns with Moody's Investors Service and Moody's Analytics to deliver a comprehensive, integrated suite of ESG and climate risk solutions including ESG scores, analytics, Sustainability Ratings and Sustainable Finance Reviewer/certifier services.
For more information visit, Moody’s ESG hub at www.moodys.com/esg .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005612/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
